An adverse-event report is a safety signal, not proof of cause
How to read safety reporting responsibly—and why suspected problems should still be taken seriously.
Educational information only — not medical advice. This material cannot diagnose a condition, recommend treatment, or replace care from a qualified clinician who knows your history. The Peptide Center uses an evidence-first editorial process that prioritizes primary regulatory sources, trial registries, and peer-reviewed research; uncertainty and evidence limits should be part of every health claim.
Safety reports can identify possible patterns that deserve investigation, but a single report does not by itself prove that a product caused an event. FDA's MedWatch program receives reports of adverse events, medication errors, and product problems; reporting helps regulators identify potential safety concerns. Learn more from FDA MedWatch.
References
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
Preparing for a peptide conversation with a clinician
A neutral question list for discussing goals, evidence, product status, and uncertainty.
Open resourceArticleEpithalon: telomere research and claim boundaries
A guide to epithalamin/epithalon aging research without turning telomere biology into a longevity promise.
Open resourceArticleThymosin alpha-1: immune-modulation research
How to evaluate immune-peptide claims while keeping research interest separate from clinical recommendations.
Open resourceArticleSS-31 (elamipretide): mitochondrial peptide research
Understanding SS-31 as an active mitochondrial-targeting research program—not a shortcut to an energy or aging claim.
Open resourceArticleNAD+ precursors and injections: research vs. product claims
A framework for reading NAD+ biology, precursor studies, and injectable product marketing side by side.
Open resource